Skip to main content

Comprehensive geriatric assessment in older patients with cancer: an external validation of the multidimensional prognostic index in a French prospective cohort study



Older patients with cancer require specific and individualized management. The 3-group Multidimensional Prognostic Index (MPI) based on the Comprehensive Geriatric Assessment (CGA) has shown a predictive interest in terms of mortality. The objective of our study was to assess the prognostic value of MPI for 1-year mortality in an external prospective French cohort of elderly patients with cancer.


From March 2015 to March 2017 a prospective single-center cohort study enrolled all patients with cancer, aged 75 years and older referred to the geriatric oncology clinic. We used a proportional hazard model for 1-year mortality adjusted for age, sex, tumor sites and metastatic status. C-statistics were used to assess the incremental predictive value of MPI index to these risk factors.


overall, 433 patients underwent CGA with MPI (women 42%; mean age 82.8 ± 4.8 years). The most common tumor sites were prostate (23%), skin (17%), colorectum (15%) and breast (12%); 29% of patients had a metastatic disease; 231 patients (53%) belonged to the “MPI-1” group, 172 (40%) to the “MPI-2” group and 30 patients were classified in the “MPI-3” group. One-year mortality rate was 32% (23% in MPI-1, 41% in MPI-2 and 53% in MPI-3, p = 0.024). All domains of MPI except cognition and living status were significantly associated with mortality at one-year, as well as tumor sites and metastatic status. Higher MPI was associated with a higher mortality risk (adjusted HR 1.56 [95%CI 1.70–2.09] and 1.72 [1.33–2.22] for MPI groups 2 and 3 compared to 1; p < 0.0001).


In addition to established risk factors, MPI improves risk prediction of 1-year mortality. This practical prognostic tool may help to optimize management of these vulnerable patients.

Peer Review reports


Individuals over 65 years old are the fastest growing segment of the population, and by 2030 will represent about 20% of Americans and 25% of Europeans [1]. The incidence of cancer continues to increase worldwide: it is estimated at 23.6 million/year by 2030, representing an increase of 68% in cases compared with 2012 [2]. The incidence of cancer is 11 times higher in people over 65 years old, and people aged 70 and older have a higher risk of developing invasive cancer [3].

The older population is characterized by a very heterogeneous profile, especially in terms of frailty, geriatric characteristics, and comorbidities, which explains the need for specific and adapted care [4, 5]. Nevertheless, scientific data are scarce because older subjects are often under-represented in oncological clinical trials that set the standards of antineoplastic treatment [6, 7].

Over the last three decades, the five-year survival rate for all types of cancer has increased, particularly in individuals aged 50 to 64 [3, 8]. Still, older patients are at more risk of toxicity in anti-cancer therapies such as chemotherapy, and require a benefit/risk assessment prior to treatment [4]. A comprehensive geriatric assessment (CGA) is consequently recommended in these patients to diagnose comorbidities and optimize geriatric interventions, and to improve the functional state and possibly the survival rate, by ensuring better tolerance to treatment [9, 10]. CGA has also shown predictive value in identifying elderly patients with cancer who are exposed to a poor prognosis, including a higher risk of death during hospitalization [11]. Among the CGA-based assessment tools, the Multidimensional Prognostic Index (MPI) has shown a predictive interest in mortality at 6 months and 12 months in Italian patients aged 70 years and older with advanced cancers [12,13,14,15].

The main objective of our study was to validate the prognostic value of the MPI for 1-year mortality in an external French cohort of older patients with cancer. The secondary objective was to assess the major risk factors associated with 12-month mortality in these patients.


Study population and data collection

This prospective single-center cohort study enrolled from March 2015 to March 2017 all patients with cancer, aged 75 years and older, who were referred to the geriatric oncology clinic of Poitiers University Hospital, prior to planned anti-cancer treatment. Socio-demographic data and cancer-related information were collected during the consultation, including age, sex, marital status, social environment, type of cancer, metastasis status, and cancer-specific treatment. Tumor sites were classified as follows: colorectal, breast, prostate, upper gastrointestinal tract (stomach and esophagus) and liver, urinary system (bladder, upper urinary tract, and kidney), hematologic malignancies, and other tumors (including ovary, uterus, lung, head and neck, skin, thyroid, and unknown primary). The CGA was performed by a senior geriatrician specialized in oncology and provided data necessary to calculate MPI. All eligible patients who had signed the consent form were included in the study. The study protocol was validated by the Poitiers University Hospital ethics committee, Poitiers, France. All the clinical and biological data were collected and recorded in a cohort database.

Multidimensional prognostic index

The MPI, based on a CGA, was calculated after administration of standardized and validated tests exploring eight domains (Table 1) [14]. Living status was categorized as “living with family”, “institutionalized” or “alone”, and functional status was evaluated by Activities of Daily Living (ADL) ranging from 0 (total dependence) to 6 (independence) and Instrumental ADL (IADL) [16, 17]. Nutrition was assessed by the Mini Nutritional Assessment-Short Form (MNA-SF) questionnaire; cognitive status was evaluated by the Short Portable Mental Status Questionnaire (SPMSQ) [18, 19]. The Exton-Smith Scale (ESS) estimated the risk of pressure ulcer [20]. Comorbidities were evaluated by the Cumulative Illness Rating Scale (CIRS), which scores the severity of 14 organic systems, ranging from 0 (absent) to 4 (most severe) [21]. Based on this scale, a comorbidity index (CIRS-CI) records the number of moderate to severe organ pathologies (CIRS scores from 2 to 4) [22]. The number of medications is classified in three groups: “≤3 drugs a day”, “4 to 6 drugs” or “≥7 drugs”.

Table 1 Multidimensional Prognostic Index score assigned to each domain according to the severity of problem

The MPI was scored by matching the results of these tests. A value of “0”, “0.5” or “1” was assigned according to the conventional cutoff points, considering “0” as no problem, “0.5” minor problem and “1” major problem (Table 1). The sum was then divided by 8 to obtain the final MPI score, which was categorized into 3 groups: the “MPI-1” group (final score ≤ 0.33, defining patients with low mortality risk at 1 year), the “MPI-2” group (0.34–0.66, moderate risk) and the “MPI-3” group (group > 0.66, higher risk).

Definition of outcomes

The primary outcome in the longitudinal analyses was 1-year mortality. Systematic follow-up was performed after discharge through clinical visits every 6 months by the same clinical research assistant. When patients were not present at visit, phone calls were made to the general practitioners to assess vital status and to obtain the date of death if applicable.

Statistical analysis

Descriptive statistics were reported as mean ± standard deviation (SD) or median (25th–75th percentiles) for continuous variables or absolute number and percentage for categorical variables. The time to event was plotted as Kaplan-Meier survival curves according to MPI groups, and comparison was made using the log-rank test. The hazard ratio (HR) of 1-year mortality for each parameter was determined by Cox proportional hazards regression. Two models were used: univariate model, and models adjusted for age, sex, metastatic status, tumor sites. Interactions between sex, tumor site and metastatic status for the association between MPI and 1-year mortality were evaluated by the addition of interaction terms into the corresponding regression model. The Akaike’s information criterion (AIC) was used to compare global fit among models (with and without MPI), and the model with the smallest AIC was considered as the best model.

Generalized c-statistics were calculated to assess improvement in 1-year mortality risk prediction of MPI in addition to traditional risk factors: age, sex, metastatic status, tumor sites [23]. The 95% CIs for the changes in the c-statistic were computed based on 1000 bootstrap samples. P values < 0.05 were considered statistically significant. Statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC).


Baseline characteristics of study population

During the recruitment period, 433 eligible patients aged 75 years and older were included, mostly males (n = 252, 58%), with a mean age of 82.8 ± 4.8 years (Table 2). The most common tumor sites were prostate (23%), skin (17%) and breast (12%); 29% of patients had a metastatic disease. Anti-cancer treatment included chemotherapy in 162 patients (37%), surgery in 137 (32%) and radiotherapy in 109 (25%). Patients had comorbid conditions regarding the CIRS-scale and medication and were frequently malnourished (29%) (Table 2). In this cohort, 231 patients (53%) were classified in the “MPI-1” group, 172 patients (40%) in “MPI-2” and 30 patients in “MPI-3”. Except for metastatic status and antineoplastic treatments, all variables of interest differed between the three MPI groups (P ≤ 0.02).

Table 2 Patients’ baseline characteristics and evaluation by multidimensional prognostic index MPI (n = 433)

MPI and 1-year mortality

Among the 433 patients, 12 were lost to follow-up (3%). Mean follow-up was 13.7 ± 6.4 months. Overall mortality at 12 months was 32% (23% in MPI-1, 41% in MPI-2 and 53% in MPI-3, P = 0.02) (Fig. 1).

Fig. 1

Kaplan-Meier curves of overall mortality in 433 patients according to MPI groups. Dotted line, MPI 1; dashed line, MPI 2 and solid line, MPI 3. Log-rank test P < 0.0001

Since we observed significant statistical interaction between sex and tumor site (P = 0.01), we presented results for the multivariate model with the inclusion in the model of an interaction term. We found no significant interaction between tumor site and metastatic status (P = 0.98).

The risk of 1-year mortality across MPI groups is shown in Fig. 1.

All functional scoring but SPMSQ and living status, number of daily drugs, metastatic status and tumor site were significantly associated with mortality (Table 3). Compared to colorectal cancer (reference category), breast cancer was associated with significantly lower 1-year mortality and upper gastrointestinal tract/liver cancer and other malignancies with significantly higher 1-year mortality.

Table 3 Univariate and multivariate analyses for one-year mortality, model for MPI-groups (n = 433)

MPI groups were associated with 1-year mortality in the univariate model and remained significantly associated even after adjustment for age, sex, metastatic status and tumor site. Compared to the MPI-1 group, patients of the MPI-2 and MPI-3 groups had gradual increased risk of 1-year mortality (adjusted hazard ratio [95%CI], 2.06 [1.42–2.98] and 4.34 [2.41–7.82], respectively, P < 0.0001) (Table 3).


We assessed improvement in risk discrimination for the MPI group compared with the model with traditional risk factors (age, sex, metastatic status and tumor site). We observed a small but significant improvement in 1-year mortality risk prediction (difference in C-statistic = 0.027, P= 0.001), when including the MPI group in the model (Table 4).

Table 4 Predictive performance of MPI during 12-month follow-up

Discussion and implications

Our study confirmed the predictive value of the multidimensional prognostic index for 1-year mortality in older patients with cancer. MPI group 3 had a significantly two- to five-fold higher rate of 1-year mortality. We also showed that the MPI improved prediction of 1-year mortality, going beyond the traditional risk factors reported in the literature [24].

Estimation of patient survival at time of the therapeutic decision is required to assess the balance of benefits and risks of performing or not performing specific oncologic interventions, taking cancer-specific mortality into consideration. Clinicians may need to know if the patient will die of cancer or with cancer, in cases where comorbidities or geriatric syndromes are challenging. Several scales have been created and validated in large epidemiologic cohorts to estimate overall survival, notably at 12 months with the Carey and Walter indexes [5, 25, 26]. These two scores consider dependency, comorbidities with cancer, and malnutrition. Walter and collaborators reported independent associations between one-year mortality in multivariable analysis and risk factors, including male gender, two medical diagnoses: congestive heart failure (aOR 1.4 (95%CI 1.1–1.8)), and cancer (aOR 2.6 (1.7–3.9)) for localized cancer and aOR 13.4 (6.2–29.0), for metastatic cancer), functional dependency in any ADL at discharge (aOR 2.1 (1.6–2.8), for dependencies from 1 to 4 ADLs, and aOR 5.7 (4.2–7.7), for dependencies in all ADLs), and 2 laboratory values: creatinine level > 3.0 mg/dL [265.2 μmol/L], aOR 1.7 (1.2–2.3)) and albumin level ≤ 3.4 g/dL, aOR 1.7 (1.2–2.3), from 3.0 to 3.4 g/dL and aOR 2.1 (1.4–3.0), for values below 3.0 g/dL) [5]. Carey et al. confirmed these findings and furthered the elaboration of a prognostic index for mortality in community-living frail older individuals, considering eight independent risk factors of mortality, weighted using Cox regression: male sex, dependence in toileting, malignant neoplasm, and renal insufficiency [25]. None of these tests were specifically developed in cohorts with individuals with cancer, and they may consequently not be informative enough to reflect clinical and functional variability in daily care and to provide personalized corrective interventions. Recent evidence reported a positive impact of geriatric interventions and monitoring in survival increase, improvement of quality of life, and completion of chemotherapy [27, 28]. The MPI differs from other mortality indexes because it is based on a CGA, with each of the eight tests assessing one geriatric domain. Giantin and collaborators confirmed the good discriminatory power for 12-month mortality in a cohort of 160 cancer patients older than 70, and validated higher mortality prediction compared to a standard CGA [13]. Use of the MPI in clinical practice may provide rapid and comprehensive evaluation of patients, and help to adapt decision-making in oncology.

The MPI has been developed and validated in large cohorts of in and outpatients for many causes, to predict not only mortality but also length of hospital stay (P = 0.011), care intensity, institutionalization, re-hospitalization, and access to homecare services [29, 30]. In an international multicenter cohort of 1140 hospitalized older patients, patients in group MPI-2 (OR 3.32 (1.79–6.17), P < 0.001) and the MPI-3 group (OR 10.72 (5.70–20.18), P < 0.0001) were at higher risk of overall mortality; compared to those of the lower risk group at admission [30]. This index may be used as a decision-making tree for cancer management, so as to select older patients with lower mortality risk for the same standard treatment as younger counterparts, those who could benefit from adapted care, or an exclusively supportive strategy in patients with limited life expectancy. This classification in three groups is comparable to the geriatric oncology algorithm of Balducci [4]. This algorithm defines three groups of patients (robust, vulnerable and frail) according to seven criteria: age, dependence measured by ADL and IADL, comorbidities with CIRS-CI, cognition evaluated with MMSE (mini-mental state examination) or delirium, depressive mood, urinary and fecal incontinence, and falls in the last 6 months. Risk of death increased steadily from the lowest to the highest category: compared to the fit group, the patients with a vulnerable profile had a two-fold mortality risk (HR 1.91 (0.95–3.85)) and a three-fold risk in the frail group (HR 2.94 (1.59–5.43), P < 0.001) [31]. More recent classifications were suggested to improve global management for such individuals, including nutrition data and cognitive assessment [25, 31].

Indeed, malnutrition is highly prevalent in geriatric oncology settings [32]. This geriatric syndrome is a well-known risk factor for early mortality. Our findings confirmed that one-year mortality is strongly associated with nutritional status and altered MNA in its short form. Some questions in this test were selected for the elaboration of the Geriatric-8 (G8) index, to screen for vulnerability in older patients with cancer, as recommended by the International Society for Geriatric Oncology (SIOG) [33, 34].

The findings of this study should be interpreted with caution. First, its design as an observational single-center study may limit the extrapolation of our results to a more general older population with cancer. Recruited patients in this cohort may not be representative, as cancer specialists may not refer all their patients to the geriatric oncology clinic, notably those screened as “not-vulnerable” in geriatric terms, as recommended by the SIOG and National Institute of Cancer in a two-step approach [33]. Cancer management of these patients may follow standard strategy, without geriatric expertise. After accounting for traditional risk factors, the magnitude of the improvement in risk prediction by the addition is small but significant. Moreover, our results are consistent with existing findings in geriatric oncology settings.

Our research on the predictive value of MPI for one-year mortality of older patients with cancer should serve as a foundation for future studies aiming to improve therapeutic strategies for these patients. A major part of this strategy involves personalized geriatric interventions, such as specific care monitoring by nurse and physical rehabilitation. It has shown benefits for elderly cancer patients, but so far, no study has demonstrated any impact on survival [35,36,37]. MPI appears to be a rapid assessment tool helping to optimize cancer care, guide patient-tailored interventions, and predict early mortality. These findings should pave the way for prospective interventional studies, taking account of MPI groups for decision-making about cancer treatments and follow-up.


In addition to established risk factors, MPI improves risk prediction of 1-year mortality in older cancer patients. This practical prognostic tool may help to optimize management of these vulnerable individuals.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.



Activities of Daily Living


Akaike’s information criterion


Comprehensive Geriatric Assessment


confidence interval


Cumulative Illness Rating Scale


Cumulative Illness Rating Scale - comorbidity index


Exton-Smith Scale




Hazard ratio


Instrumental Activities of Daily Living


Mini Nutritional Assessment-Short Form


Multidimensional Prognostic Index


Standard deviation


International society of geriatric oncology


Short Portable Mental Status Questionnaire


  1. 1.

    Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.

    PubMed  Article  Google Scholar 

  2. 2.

    Cancer Research UK. Worldwide cancer incidence statistics. 2015. Available from wide-cancer/ incidence. Accessed 30 Apr 2020.

  3. 3.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.

    PubMed  Article  Google Scholar 

  4. 4.

    Balducci L, Extermann M. Management of Cancer in the older person: a practical approach. Oncologist. 2000;5:224–37.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Walter LC, Brand RJ, Counsell SR, Palmer RM, Landefeld CS, Fortinsky RH, et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA. 2001;285:2987–94.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Gouverneur A, Salvo F, Berdaï D, Moore N, Fourrier-Réglat A, Noize P. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: a systematic review. J Geriatr Oncol. 2018;9:15–23.

    PubMed  Article  Google Scholar 

  7. 7.

    Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.

    PubMed  Article  Google Scholar 

  8. 8.

    Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute surveillance, epidemiology, and end results (SEER) program in the United States, 1990 to 2010. JAMA Oncol. 2015;1:88–96.

    PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Ellis G, Gardner M, Tsiachristas A, Langhorne P, Burke O, Harwood RH, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev. 2017;9:CD006211.

    PubMed  Google Scholar 

  10. 10.

    Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2595–603.

    PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Avelino-Silva TJ, Farfel JM, Curiati JA, Amaral JR, Campora F, Jacob-Filho W. Comprehensive geriatric assessment predicts mortality and adverse outcomes in hospitalized older adults. BMC Geriatr. 2014;14:129.

    PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Angleman SB, Santoni G, Pilotto A, Fratiglioni L, Welmer AK; MPI_AGE Project Investigators. Multidimensional Prognostic Index in Association with Future Mortality and Number of Hospital Days in a Population-Based Sample of Older Adults: Results of the EU Funded MPI_AGE Project. PLoS One. 2015;10:e0133789.

  13. 13.

    Giantin V, Falci C, De Luca E, Valentini E, Iasevoli M, Siviero P, Maggi S, et al. Performance of the multidimensional geriatric assessment and multidimensional prognostic index in predicting negative outcomes in older adults with cancer. Eur J Cancer Care. 2016:1–8.

  14. 14.

    Pilotto A, Ferrucci L, Franceschi M, D'Ambrosio LP, Scarcelli C, Cascavilla L, et al. Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients. Rejuvenation Res. 2008;11:151–61.

    PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Pilotto A, Rengo F, Marchionni N, Sancarlo D, Fontana A, Panza F, et al. Comparing the prognostic accuracy for all-cause mortality of frailty instruments: a multicentre 1-year follow-up in hospitalized older patients. PLoS One. 2012;7:e29090.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10:20–30.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc. 1975;23:433–41.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Rubenstein LZ, Harker JO, Salva A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). J Gerontol A Biol Sci Med Sci. 2001;56:M366–72.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Bliss MR, McLaren R, Exton-Smith AN. Mattresses for preventing pressure sores in geriatric patients. Mon Bull Minist Health Public Health Lab Serv. 1966;25:238–68.

    CAS  PubMed  Google Scholar 

  21. 21.

    Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622–6.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Conwell Y, Forbes NT, Cox C, Caine ED. Validation of a measure of physical illness burden at autopsy: the cumulative illness rating scale. J Am Geriatr Soc. 1993;4:38–41.

    Article  Google Scholar 

  23. 23.

    Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109–23.

    PubMed  Article  Google Scholar 

  24. 24.

    Giantin V, Valentini E, Iasevoli M, Falci C, Siviero P, De Luca E, et al. Does the multidimensional prognostic index (MPI), based on a comprehensive geriatric assessment (CGA), predict mortality in cancer patients? Results of a prospective observational trial. J Geriatr Oncol. 2013;4:208–17.

    PubMed  Article  Google Scholar 

  25. 25.

    Carey EC, Covinsky KE, Lui LY, Eng C, Sands LP, Walter LC. Prediction of mortality in community-living frail elderly people with long-term care needs. J Am Geriatr Soc. 2008;56:68–75 Epub 2007 Nov 20.

    PubMed  Article  Google Scholar 

  26. 26.

    Pamoukdjian F, Liuu E, Caillet P, Herbaud S, Gisselbrecht M, Poisson J. How to optimize Cancer treatment in older patients: an overview of available geriatric tools. Am J Clin Oncol. 2019;42:109–16.

    PubMed  Article  Google Scholar 

  27. 27.

    Kalsi T, Babic-Illman G, Ross PJ, Maisey NR, Hughes S, Fields P. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015;112:1435–44.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Rao AV, Hsieh F, Feussner JR, Cohen HJ. Geriatric evaluation and management units in the care of the frail elderly cancer patient. J Gerontol A Biol Sci Med Sci. 2005;60:798–803.

    PubMed  Article  Google Scholar 

  29. 29.

    Meyer AM, Becker I, Siri G, Brinkkötter PT, Benzing T, Pilotto A, Polidori MC. New associations of the Multidimensional Prognostic Index. Z Gerontol Geriatr 2019;52:460–7.

  30. 30.

    Pilotto A, Veronese N, Daragjati J, Cruz-Jentoft AJ, Polidori MC, Mattace-Raso F, et al. Using the multidimensional prognostic index to predict clinical outcomes of hospitalized older persons: a prospective, multicentre, international study. J Gerontol A Biol Sci Med Sci. 2018;60:80–5.

    Google Scholar 

  31. 31.

    Ferrat E, Paillaud E, Caillet P, Laurent M, Tournigand C, Lagrange JL, et al. Performance of four frailty classifications in older patients with cancer: prospective elderly cancer patients cohort study. J Clin Oncol. 2017;35:766–77.

    PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Caillet P, Liuu E, Raynaud Simon A, Bonnefoy M, Guerin O, Berrut G. Association between cachexia, chemotherapy and outcomes in older cancer patients: a systematic review. Clin Nutr. 2017;36:1473–82.

    PubMed  Article  Google Scholar 

  33. 33.

    Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26:288–300.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, et al. Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS One. 2014;9:e115060.

    PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol. 2011;29:3636–42.

    PubMed  Article  Google Scholar 

  36. 36.

    Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28:340–7.

    PubMed  Article  Google Scholar 

  37. 37.

    Goodwin JS, Satish S, Anderson ET, Nattinger AB, Freeman JL. Effect of nurse case management on the treatment of older women with breast cancer. J Am Geriatr Soc. 2003;51:1252–9.

    PubMed  Article  Google Scholar 

Download references


Authors thank Emilie Favard for her assistance in the collection of follow-up data, and Jeffrey Arsham who edited the English of the manuscript.


The authors declare no funding.

Author information




EL, CH and MP designed the study. EL, SV and AJ were responsible for the acquisition of data. EL and PJS performed the statistical analysis and interpretation. EL, PJS and MP wrote the manuscript. EL, PJS, MP, TB, MLB and AP substantively revised the work. All authors (EL, CH, SV, TB, AJ, MLB, AP, PJS and MP) read and approved the final manuscript.

Corresponding author

Correspondence to Evelyne Liuu.

Ethics declarations

Ethics approval and consent to participate

All eligible patients who had signed the consent form were included in the study. The study protocol was validated by the Poitiers University Hospital ethics committee, Poitiers, France.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liuu, E., Hu, C., Valero, S. et al. Comprehensive geriatric assessment in older patients with cancer: an external validation of the multidimensional prognostic index in a French prospective cohort study. BMC Geriatr 20, 295 (2020).

Download citation


  • Aged
  • Neoplasms
  • Mortality
  • Comprehensive geriatric assessment